Related Experiment Videos
Thrombolytic agents and anticoagulants
1Thrombosis Research Center, University of Massachusetts Medical School, Worcester 01655.
Cardiovascular Drugs and Therapy
|November 1, 1993
Summary
Researchers are developing targeted "designer" thrombolytic and anticoagulant therapies to safely and effectively treat atherosclerotic coronary artery disease. These novel agents aim to precisely modulate thrombosis and fibrinolysis, with clinical trials anticipated soon.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biochemistry
Background:
- Thrombosis plays a critical role in the development and manifestation of atherosclerotic coronary artery disease.
- Current therapeutic strategies focus on anticoagulants and thrombolytic agents.
Purpose of the Study:
- To develop novel, safe, effective, and affordable thrombolytic agents and anticoagulants.
- To design "designer" compounds that specifically target key components of thrombotic and fibrinolytic pathways.
Main Methods:
- Development of new compounds, mutants, and derivatives.
- Targeted modulation of thrombotic and fibrinolytic processes.
- Focus on precise impairment, neutralization, or enhancement of specific molecular targets.
Main Results:
- Intense research efforts are underway to create advanced therapeutic agents.
- The design strategy emphasizes specificity and controlled action rather than broad inhibition.
- Anticipation of novel "designer" agents with improved safety and efficacy profiles.
Conclusions:
- The development of targeted thrombolytics and anticoagulants is progressing rapidly.
- These novel agents hold promise for improved management of atherosclerotic coronary artery disease.
- Clinical trials for advanced "designer" therapies are expected in the near future.